News >

Glembatumumab Vedotin Induces 61% DCR in Uveal Melanoma

Jason Harris
Published: Friday, Oct 27, 2017

Sapna Pradyuman Patel, MD
Sapna Pradyuman Patel, MD
Glembatumumab vedotin (CDX-011) induced a disease control rate (DCR) of 61% in patients with metastatic uveal melanoma, despite a low a low objective response rate (ORR) of 6%, according to results from the the phase II NCI9855 study.

She added that exploratory immune correlates are underway to provide insight into combination strategies and induction of antigen release.
Patel S. A phase II study of glembatumumab vedotin for metastatic uveal melanoma. Presented at: 2017 World Congress of Melanoma; October 18-21, 2017; Brisbane, Australia. Presentation SMR09-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x